A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. by Svensson, T, Chowdhury, O, Garelius, H, Lorenz, F, Saft, L, Jacobsen, SE, Hellström-Lindberg, E, Cherif, H

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome by Hoeks, M, Bagguley, T, van Marrewijk, C, Smith, A, Bowen, D, Culligan, D, Kolade, S, Symeonidis, A, Garelius, H, Spanoudakis, M, Langemeijer, S, Roelofs, R, Wiegerinck, E, Tatic, A, Killick, S, Panagiotidis, P, Stanca, O, Hellström-Lindberg, E, Cermak, J, van der Klauw, M, Wouters, H, van Kraaij, M, Blijlevens, N, Swinkels, DW, de Witte, T, EUMDS Registry Participants, Stauder, R, Walder, A, Pfeilstöcker, M, Schoenmetzler-Makrai, A, Burgstaller, S, Thaler, J, Mandac Rogulj, I, Krejci, M, Voglova, J, Rohon, P, Jonasova, A, Cermak, J, Mikulenkova, D, Hochova, I, Jensen, PD, Holm, MS, Kjeldsen, L, Dufva, IH, Vestergaard, H, Re, D, Slama, B, Fenaux, P, Choufi, B, Cheze, S, Vyas, P